Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H12O6 |
Molecular Weight | 180.1559 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O
InChI
InChIKey=GZCGUPFRVQAUEE-SLPGGIOYSA-N
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2/t3-,4+,5+,6+/m0/s1
DescriptionSources: http://www.medicinenet.com/glucose/page2.htmCurator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Glucose
Sources: http://www.medicinenet.com/glucose/page2.htm
Curator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Glucose
Glucose is a sugar with the molecular formula C6H12O6. The D-isomer (D-glucose), also known as dextrose, occurs widely in nature, but the L-isomer (L-glucose) does not. Glucose is made during photosynthesis from water and carbon dioxide, using energy from sunlight. The reverse of the photosynthesis reaction, which releases this energy, is a very important source of power for cellular respiration. Glucose is stored as a polymer, in plants as starch and in animals as glycogen, for times when the organism will need it. Glucose circulates in the blood of animals as blood sugar. Glucose can be obtained by hydrolysis of carbohydrates such as milk, cane sugar, maltose, cellulose, glycogen etc. It is however, manufactured by hydrolysis of cornstarch by steaming and diluting acid. Glucose is the human body's key source of energy, through aerobic respiration, providing about 3.75 kilocalories (16 kilojoules) of food energy per gram. Breakdown of carbohydrates (e.g. starch) yields mono- and disaccharides, most of which is glucose. Use of glucose as an energy source in cells is by either aerobic respiration, anaerobic respiration, or fermentation. All of these processes follow from an earlier metabolic pathway known as glycolysis. The insulin reaction, and other mechanisms, regulate the concentration of glucose in the blood. Glucose supplies almost all the energy for the brain, so its availability influences psychological processes. When glucose is low, psychological processes requiring mental effort (e.g., self-control, effortful decision-making) are impaired. Ingested glucose is absorbed directly into the blood from the intestine and results in a rapid increase in the blood glucose level. Glucose is used to manage hypoglycemia and for intravenous feeding. Nausea may occur after ingesting glucose, but this also may be an effect of the hypoglycemia which is present just prior to ingestion. Other adverse effects include increased blood glucose, injection site leakage of fluid (extravasation), injection site inflammation, and bleeding in the brain.
CNS Activity
Sources: http://neuroscience.uth.tmc.edu/s4/chapter11.html
Curator's Comment: Glucose from blood enters the brain by a transport protein. Glucose is the primary energy substrate of the brain. Glucose transport protein (GLUT-1) is highly enriched in brain capillary endothelial cells. These transporters carry glucose molecules through the blood brain barrier. Although rare, patients with Glut-1 deficiency (caused by genetic mutations) can have severe learning difficulties. Low glucose sugar levels in the cerebrospinal, but not in the blood, will identify the condition.
Originator
Curator's Comment: In the year 1747, a pharmacist from Germany named Andreas Marggraf was able to isolate the glucose found in raisins. However, Marggraf called it as ‘eine Art Zucke’. In 1811, sugar syrup was produced by Constantine Kirchoff with the use of isolated glucose. It was only in 1838 when the term ‘glucose’ was introduced and this was done by Jean Baptiste Andre Dumas. The word was derived from a Greek word glycos that means sweet.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map00010 Sources: http://www.ncbi.nlm.nih.gov/books/NBK22395/ |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | ALCOHOL AND DEXTROSE Approved UseAlcohol and Dextrose Injections USP are indicated for increasing caloric intake. |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg/kg single, oral Highest studied dose Dose: 400 mg/kg Route: oral Route: single Dose: 400 mg/kg Sources: |
healthy, <1 h old n = 73 Health Status: healthy Condition: Neonatal Hypoglycaemia Prophylaxis Age Group: <1 h old Sex: M+F Population Size: 73 Sources: |
|
25 g single, intravenous Highest studied dose Dose: 25 g Route: intravenous Route: single Dose: 25 g Sources: |
unhealthy Health Status: unhealthy Condition: Hypoglycaemia Sources: |
|
10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: |
unhealthy n = 25 Health Status: unhealthy Condition: Adult hypoglycaemia Sex: M+F Population Size: 25 Sources: |
|
10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
Other AEs: Fluid overload, Electrolytes serum low (NOS)... Other AEs: Fluid overload Sources: Page: p.2Electrolytes serum low (NOS) Overhydration Pulmonary edema Peripheral edema Hypokalemia (grade 3) Serum osmolality increased Intracerebral hemorrhage |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Electrolytes serum low (NOS) | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
|
Fluid overload | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
|
Intracerebral hemorrhage | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
|
Overhydration | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
|
Peripheral edema | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
|
Pulmonary edema | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
|
Serum osmolality increased | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
|
Hypokalemia | grade 3 | 10 % single, intravenous Recommended Dose: 10 % Route: intravenous Route: single Dose: 10 % Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Source of water and calories Sources: Page: p.2 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/19965590/ |
yes |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.medicinenet.com/glucose/page2.htm
Curator's Comment: The usual dose of glucose for hypoglycemia is 10-20 gm orally or by intravenous infusion.
Intravenous solution/Injection: 2.5 %, 5 %, 10 %, 20 %, 25 %, 30 %, 40 %, 50 %, 70 %
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/26141922
Erythrocytes were incubated with 5, 45 or 100 mM glucose for up to 72 h. High glucose concentrations intensified lipid peroxidation and loss of activities of erythrocyte enzymes (glutathione S-transferase and glutathione reductase).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
40366-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
77135-2
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2341-6
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
21307-4
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
35662-6
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
15077-1
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2348-1
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
48036-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
35211-2
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
16903-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
6300-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
25916-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14743-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
45297-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
47620-0
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
CFR |
21 CFR 862.1345
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
||
|
LOINC |
34312-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14386-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
62418-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
12629-2
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
||
|
LOINC |
18227-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
47995-6
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
41651-1
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14749-6
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
39480-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
NCI_THESAURUS |
C344
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
41652-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
53050-1
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
12628-4
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
||
|
LOINC |
39481-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
74686-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
55860-1
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14747-0
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2344-0
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
72516-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
NCI_THESAURUS |
C68479
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
FDA ORPHAN DRUG |
780220
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
||
|
FDA ORPHAN DRUG |
599517
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
||
|
LOINC |
57797-3
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
54486-6
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2351-5
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
33405-2
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
15075-5
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14750-4
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
21306-6
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2349-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
43740-0
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2339-0
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
74351-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
57004-4
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
DSLD |
1109 (Number of products:112)
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
||
|
LOINC |
54487-4
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2345-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
58997-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14745-4
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14746-2
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
41653-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
32318-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2350-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
51596-5
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
33352-6
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14744-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2342-4
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
6777-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
40488-9
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2340-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
CFR |
21 CFR 168.110
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
||
|
LOINC |
35212-0
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
51595-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
32174-5
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
5914-7
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
21305-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
15076-3
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
32016-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
39479-1
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
53084-0
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
14748-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
15074-8
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
74774-1
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
74687-5
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2347-3
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2346-5
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
39478-3
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
||
|
LOINC |
2343-2
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5765
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
349730
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
50-99-7
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
5SL0G7R0OK
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
4167
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
DTXSID7022910
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
5SL0G7R0OK
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
SUB74890
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
489
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
2280-44-6
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
SUPERSEDED | |||
|
17234
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
107526
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
PRIMARY | |||
|
C61716
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
PRIMARY | |||
|
1181302
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
PRIMARY | |||
|
SUB11988MIG
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
100000078171
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
PRIMARY | |||
|
845
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
42758
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
218-914-5
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
ALTERNATIVE | |||
|
406891
Created by
admin on Fri Dec 15 15:39:58 GMT 2023 , Edited by admin on Fri Dec 15 15:39:58 GMT 2023
|
PRIMARY | |||
|
17634
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
DB01914
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
200-075-1
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY